Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ABBV
- Price
- 218.11
- Stock movement up
- +4.00 (1.76%)
- Company name
- AbbVie Inc
- Exchange
- (NYSE ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - General
- Market cap
- 409.15B
- Ent value
- -
- Price/Sales
- 6.69
- Price/Book
- -
- Div yield
- 2.99%
- Div growth
- 6.81%
- Growth years
- 9
- FCF payout
- 68.31%
- Trailing P/E
- 96.82
- Forward P/E
- 14.48
- PEG
- 11.71
- EPS growth
- -2.03%
- 1 year return (CAGR)
- 19.95%
- 3 year return (CAGR)
- 16.98%
- 5 year return (CAGR)
- 16.72%
- 10 year return (CAGR)
- 15.86%
Last updated: 2026-02-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
BUSINESS INSIGHT
Revenues per Product Category ($M)
Loading...
Company comments
AbbVie was created through a spinoff from Abbott Laboratories in 2013
Humira is the world’s #1 global pharmaceutical product by a large margin
AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications
Geographic Revenues ($M)
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
Dividend yield - 5y
Loading...
Dividend yield data
| Dividend per share | 6.92 |
| Dividend yield | 2.99% |
| Payout frequency | Quarterly |
| Maximum yield | 5.25% |
| Average yield | 3.85% |
| Minimum yield | 2.68% |
| Discount to avg yield | -28.75% |
| Upside potential | -22.33% |
| Yield as % of max yield | 56.94% |
Yield distribution (inverse percentile) - 5y
Loading...
Yield distribution data
| Dividend yield | 2.99% |
| Current yield distribution | 96.67% |
| Yield at 100% (Min) | 2.68% |
| Yield at 90% | 3.14% |
| Yield at 80% | 3.41% |
| Yield at 50% (Median) | 3.80% |
| Yield at 20% | 4.34% |
| Yield at 10% | 4.63% |
| Yield at 0% (Max) | 5.25% |
Dividend per share
Loading...
Dividend per share data
| Years of growth | 9 years |
| CCC status | Dividend Challenger |
| Dividend per share | 6.92 |
| Payout frequency | Quarterly |
| Ex-div date | 16 Jan 2026 |
| EPS (TTM) | 2.38 |
| EPS (1y forward) | 15.99 |
| EPS growth (5y) | -2.03% |
| EPS growth (5y forward) | 8.27% |
Dividend growth
Loading...
Please create a free account or log in to access this chart
Dividend growth data
| ABBV | S&P500 | |
| DGR MR | 5.49% | -13.74% |
| DGR TTM | 5.72% | 6.60% |
| DGR 3 years | 5.17% | 7.31% |
| DGR 5 years | 6.81% | 4.69% |
| DGR 10 years | 12.50% | 6.30% |
| DGR 15 years | - | 8.16% |
| Time since last change announced | 109 days |
| EPS growth (5y) | -2.03% |
| EPS growth (5y forward) | 8.27% |
Payout ratio
Loading...
Please create a free account or log in to access this chart
Payout ratio data
| EPS coverage | FCF coverage | |
| TTM | 206.96% | 68.31% |
| Average | - | - |
| Forward | 43.28% | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 96.82 |
| Price to OCF | 29.62 |
| Price to FCF | 31.95 |
| Price to EBITDA | 33.91 |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.69 |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.77B |
| EPS (TTM) | 2.38 |
| FCF per share (TTM) | 7.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 61.16B |
| Gross profit (TTM) | 44.85B |
| Operating income (TTM) | 16.34B |
| Net income (TTM) | 4.23B |
| EPS (TTM) | 2.38 |
| EPS (1y forward) | 15.99 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 73.34% |
| Operating margin (TTM) | 26.72% |
| Profit margin (TTM) | 6.91% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 0.00 |
| Net receivables | 0.00 |
| Total current assets | 0.00 |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 0.00 |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 0.00 |
| Total liabilities | 0.00 |
| Shareholder's equity | 0.00 |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 13.81B |
| Capital expenditures (TTM) | 1.01B |
| Free cash flow (TTM) | 12.80B |
| Dividends paid (TTM) | 8.75B |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 228.42 |
| Daily high | 234.74 |
| Daily low | 228.00 |
| Daily Volume | 6.02M |
| All-time high | 244.38 |
| 1y analyst estimate | 245.33 |
| Beta | 0.33 |
| EPS (TTM) | 2.38 |
| Dividend per share | 6.92 |
| Ex-div date | 16 Jan 2026 |
| Next earnings date | 23 Apr 2026 |
Downside potential
Loading...
Downside potential data
| ABBV | S&P500 | |
| Current price drop from All-time high | -10.75% | -0.89% |
| Highest price drop | -48.88% | -56.47% |
| Date of highest drop | 15 Aug 2019 | 9 Mar 2009 |
| Avg drop from high | -13.21% | -10.86% |
| Avg time to new high | 17 days | 12 days |
| Max time to new high | 975 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
409.15B
Marketcap category
Large-cap
Description
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. AbbVie Inc. has strategic partnership with OSE Immunotherapeutics. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employees
55000
Website
Investor relations
SEC filings
CEO
Richard Gonzalez
Country
USA
City
North Chicago
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page